Browse by author
Lookup NU author(s): Dr Wei-Yu Lin
This is the final published version of an article that has been published in its final definitive form by Wiley-Liss Inc., 2018.
For re-use rights please refer to the publisher's terms and conditions.
© 2018 UICC Precision medicine requires markers for therapeutic guidance. The purpose of this study was to determine whether epithelial ovarian cancer (EOC) epigenetics can lead to the identification of biomarkers for precision medicine. Through integrative methylomics, we discovered and validated the epigenetic signature of NEFH and HS3ST2 as an independent prognostic factor for type II EOC in our dataset (n = 84), and two independent methylomics datasets (total n = 467). Integrated transcriptomics dataset (n = 1147) and tissue microarrays (n = 54) of HS3ST2 also related to high-methylation statuses and the EOC prognosis. Mechanistic explorations of HS3ST2 have assessed responses to oncogenic stimulations such as IL-6, EGF, and FGF2 in cancer cells. The combination of HS3ST2 and various oncogenic ligands also confers the worse outcome. 3-O-sulfation of heparan sulfate by HS3ST2 makes ovarian cancer cells intrinsically sensitive to oncogenic signals, which sheds new light on the application of HS3ST2 as a companion diagnostic for targeted therapy using kinase inhibitors or therapeutic antibodies.
Author(s): Huang R-L, Chen H-J, Chen L-Y, Chao T-K, Lin W-Y, Liew P-L, Su P-H, Weng Y-C, Wang Y-C, Liao C-C, Hsu Y-W, Wang H-C, Lai H-C
Publication type: Article
Publication status: Published
Journal: International Journal of Cancer
Print publication date: 15/10/2018
Online publication date: 07/05/2018
Acceptance date: 23/04/2018
Date deposited: 01/10/2018
ISSN (print): 0020-7136
ISSN (electronic): 1097-0215
Publisher: Wiley-Liss Inc.
Altmetrics provided by Altmetric